+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Pancreatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Pancreatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Male Hypogonadism - Pipeline Insight, 2025 - Product Thumbnail Image

Male Hypogonadism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hyperphosphatemia - Pipeline Insight, 2025 - Product Thumbnail Image

Hyperphosphatemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hyperparathyroidism - Pipeline Insight, 2025 - Product Thumbnail Image

Hyperparathyroidism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Phenylketonuria- Pipeline Insight, 2025 - Product Thumbnail Image

Phenylketonuria- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Somatostatin Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Somatostatin Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hypoglycemia- Pipeline Insight, 2025 - Product Thumbnail Image

Hypoglycemia- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Parathyroid Hormone Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Parathyroid Hormone Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
AL Amyloidosis- Pipeline Insight, 2025 - Product Thumbnail Image

AL Amyloidosis- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Somatotropin Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Somatotropin Deficiency - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
BRD4 Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

BRD4 Protein Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Capsid Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Capsid Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
ACVR1 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

ACVR1 Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
NLRP3 Protein Inhibitors- Pipeline Insight, 2025 - Product Thumbnail Image

NLRP3 Protein Inhibitors- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
MALT1 Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

MALT1 Protein Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
MCL1 Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

MCL1 Protein Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
ATR Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

ATR Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
ANGPTL3 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

ANGPTL3 Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more